Stifel Financial
KYTX icon

Stifel Financial’s Kyverna Therapeutics KYTX Stock Holding History

Stifel Financial’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.13M Buy
130,524
+4,734
+4% +$39.4K ﹤0.01% 2384
2025
Q4 		$1.18M Buy
125,790
+86,969
+224% +$646K ﹤0.01% 2324
2025
Q3 		$233K Sell
38,821
-144
-0.4% -$576 ﹤0.01% 3263
2025
Q2 		$120K Sell
38,965
-198
-0.5% -$490 ﹤0.01% 3346
2025
Q1 		$75.6K Sell
39,163
-179
-0.5% -$529 ﹤0.01% 3317
2024
Q4 		$147K Buy
+39,342
New +$188K ﹤0.01% 3208

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Stifel Financial's KYTX Position: Q1 2026 in Review

Stifel Financial increased its Kyverna Therapeutics (KYTX) stake by 3.8% in Q1 2026, buying an estimated $39.4K and bringing the position to 130,524 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2384.

Stifel Financial first reported a position in KYTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.18M in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Stifel Financial held 130,524 shares of Kyverna Therapeutics worth $1.13M as of Q1 2026.
  • Stifel Financial bought 4,734 Kyverna Therapeutics shares in Q1 2026, an estimated $39.4K.
  • Kyverna Therapeutics made up ﹤0.01% of Stifel Financial's portfolio in Q1 2026, its #2384 holding.
  • Stifel Financial first reported a position in Kyverna Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Stifel Financial's Kyverna Therapeutics position peaked at $1.18M in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Stifel Financial's 13F filing for Q1 2026, filed 12 May 2026.